1 recruiting, 1 terminated. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow Rapa Therapeutics LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RAPA-201 Therapy of Solid Tumors RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy, Pembrolizumab (PD-1 Blocking Antibody) - Solid Tumor, Small Cell and Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Rapa Therapeutics LLC | 37 | 2021-08-01 | 2025-05-14 |
| RAPA-501-Allo Therapy of COVID-19-ARDS RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo - Severe COVID-19 Disease | Phase 1 / Phase 2 | Terminated | Rapa Therapeutics LLC | 1 | 2020-12-30 | 2021-11-11 |
Acute Lung Injury (1) · COVID-19 (1) · Carcinoma, Non-Small-Cell Lung (1) · Coronavirus Infections (1) · Cytokine Release Syndrome (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Lung Diseases (1) · Lung Injury (1) · Melanoma (1) · Pneumonia (1) · Respiratory Distress Syndrome (1) · Squamous Cell Carcinoma of Head and Neck (1)
pembrolizumab (1)
United States (2)